Biogen Completes Acquisition of Human Immunology Biosciences

“We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “With the transaction now complete, we will begin working together with our colleagues from HI-Bio on plans to advance felzartamab to phase 3 and ultimately deliver innovative treatments to patients with unmet needs across a range of rare diseases.” Read More

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences